Zoloft ® — Net Sales
Viatris Zoloft ® — Net Sales increased by 8.7% to $72.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 20.6%, from $60.20M to $72.60M. Over 4 years (FY 2021 to FY 2025), Zoloft ® — Net Sales shows a downward trend with a -2.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests strong market demand or successful pricing strategies for the brand, while a decrease may indicate increased generic competition, patent expiration impacts, or shifting therapeutic preferences.
Detailed definition
This metric represents the total revenue generated from the sale of the Zoloft brand pharmaceutical product after accoun...
Peer comparison
Similar to revenue metrics for mature, off-patent branded pharmaceuticals at other large-cap generic and specialty drug manufacturers.
vtrs_segment_zoloft_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $70.90M | $61.30M | $75.50M | $73.10M | $62.50M | $53.10M | $57.50M | $56.50M | $54.50M | $62.70M | $62.00M | $58.00M | $58.90M | $60.60M | $58.20M | $60.20M | $61.10M | $66.80M | $66.80M | $72.60M |
| QoQ Change | — | -13.5% | +23.2% | -3.2% | -14.5% | -15.0% | +8.3% | -1.7% | -3.5% | +15.0% | -1.1% | -6.5% | +1.6% | +2.9% | -4.0% | +3.4% | +1.5% | +9.3% | +0.0% | +8.7% |
| YoY Change | — | — | — | — | -11.8% | -13.4% | -23.8% | -22.7% | -12.8% | +18.1% | +7.8% | +2.7% | +8.1% | -3.3% | -6.1% | +3.8% | +3.7% | +10.2% | +14.8% | +20.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's zoloft ® — net sales?
- Viatris (VTRS) reported zoloft ® — net sales of $72.60M in Q1 2026.
- How has Viatris's zoloft ® — net sales changed year-over-year?
- Viatris's zoloft ® — net sales increased by 20.6% year-over-year, from $60.20M to $72.60M.
- What is the long-term trend for Viatris's zoloft ® — net sales?
- Over 4 years (2021 to 2025), Viatris's zoloft ® — net sales has grown at a -2.7% compound annual growth rate (CAGR), from $284.30M to $254.90M.
- What does zoloft ® — net sales mean?
- The total revenue earned from selling the Zoloft brand medication.